Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports-Reference-Cited by-同舟云学术

Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports

Published:2023-11-01 Issue:11 Volume:33 Page:1368-1373
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Moog Sophie¹^ORCID,Lamartina Livia¹,Bani Mohamed-Amine²,Al Ghuzlan Abir²,Friboulet Luc³,Italiano Antoine⁴,Lacroix Ludovic³,Postel Vinay Sophie⁴³,Tselikas Lambros⁵,Deschamps Frédéric⁵,Bonnet Baptiste⁵,Pani Fabiana¹,Baudin Eric¹,Hadoux Julien¹^ORCID

Affiliation:

1. Service d'Oncologie Endocrinienne, Département d'Imagerie, Institut Gustave Roussy, Villejuif, France.

2. Département de Biologie et Pathologie Médicale, Institut Gustave Roussy, Villejuif, France.

3. Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Villejuif, France.

4. Département d'Innovation Thérapeutique et Essais Précoces, and Institut Gustave Roussy, Villejuif, France.

5. Département de Radiologie Interventionnelle, Institut Gustave Roussy, Villejuif, France.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0144

Reference29 articles.

1. Management of advanced medullary thyroid cancer

2. Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

3. Cabozantinib in Progressive Medullary Thyroid Cancer

4. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

5. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation;2024-01-10